The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Increases speed to market for drug developers working on nucleic acid therapeutics
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Establishing Asymchem’s first manufacturing footprint in Europe
Subscribe To Our Newsletter & Stay Updated
